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Abstract
This review gives an outline of the indications for faecal microbiota transplantation (FMT) for diseases other than Clostridium difﬁcile
(C. difﬁcile) infection. The remarkable efﬁcacy of FMT against C. difﬁcile infection has already been demonstrated. The use of FMT for other
diseases, such as inﬂammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic syndrome, is now being evaluated. The
currently available data suggest that FMT might be beneﬁcial for IBD (including ulcerative colitis and, to some extent, Crohn’s disease), IBS,
and insulin resistance. Several randomized clinical trials are currently being performed, and data are eagerly awaited. A new ﬁeld of research
for the implementation of FMT is the eradication of pathogenic and multiresistant enteric microorganisms. A few animal studies have been
performed within this ﬁeld, but hardly any research data from human studies are available at present.
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Introduction
During the last few years, faecal microbiota transplantation
(FMT) also known as donor faeces transplantation or faecal
bacteriotherapy, has attracted increased attention. Themajority
of clinical experience with FMT has been gathered from the
treatment of Clostridium difﬁcile (C. difﬁcile) infection. Many case
reports, case series and meta-analyses [1,2] on this topic have
been published. Furthermore, in a recently published random-
ized controlled trial, FMT against C. difﬁcile infection was shown
to give a cure rate of 90% [3].
Other indications for FMT as a treatment option have also
been evaluated, but to different extents. In this review, we
discuss and summarize indications for FMT apart from
C. difﬁcile infection, such as inﬂammatory bowel disease
(IBD), irritable bowel syndrome (IBS), obesity, type 2 diabetes,
and colonization of the gastrointestinal tract by pathogenic and
multiresistant microorganisms. Also, the association between
these diseases and the gut microbiota alterations will be
described.
The Human Gut Microbiota
The human gut microbiota is the term used to describe the
composition of the vast amount of microorganisms residing
in the human gastrointestinal tract [4,5]. It has been
estimated that there are ten times more bacterial cells than
somatic cells in each human being, and that approximately
1.5–3 kg of the human body weight consists of bacteria, the
majority of which reside in the gastrointestinal tract. The
concentration of bacteria within the gastrointestinal tract is
lowest in the stomach and increases rapidly throughout the
course of the distal parts of the gastrointestinal tract, with
the highest concentration being in the large intestine. The
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concentration of microorganisms in the faecal mass within
the large intestine is estimated to be 1011–1012 CFU/g of
faeces [6]; furthermore, it is estimated that approximately
55% of the solid faecal mass is actually bacterial mass [7]. The
microbiota of a healthy individual shows a large diversity in its
composition. There are seven main taxonomic divisions of
the resident bacteria [4] (i.e. Firmicutes, Bacteroidetes, Prote-
obacteria, Fusobacteria, Verrucomicrobia, Cyanobacteria, and
Actinobacteria). The majority of the microbiota consists of
members of the Firmicutes and Bacteroidetes [4,8]. The
composition of the gut microbiota is mainly dependent on
the diet of the host [9–11]; however, there is evidence that
age [12] is also a determinant.
Many conditions, of which the use of antibiotics is the
best-known example, are able to disrupt and alter the
composition of the gut microbiota. The majority of the gut
microbiota is located within the large intestine, and has
various functions that are thought to be beneﬁcial for the host.
The most well-known function is the degradation of
non-digestible food remnants (resistant starch) and the
consequent production of certain vitamins such as vitamin K.
As result of recent advances in molecular techniques, such as
16S ribosomal RNA sequencing-based methods and shotgun
metagenome sequencing, it has become clear that the gut
microbiota also has a variety of other functions in the ﬁeld of
host defence, energy metabolism, and immune system devel-
opment [4]. From this, it follows that disruption or alteration
in the composition of the gut microbiota may underlie various
diseases, such as gastrointestinal infections, metabolic disor-
ders, and IBDs.
IBD
IBD consists primarily of Crohn’s disease (CD) and ulcerative
colitis, and is characterized by chronic inﬂammation. Increasing
evidence supports the association between the composition of
the gut microbiota and IBD [4,13]. It has been shown that the
gut microbiota of IBD patients is less diverse and has reduced
amounts of members of the Firmicutes and Bacteroidetes as
compared with the microbiota of healthy individuals [14].
More importantly, the differences observed in the gut
microbiota of IBD patients, in comparison with the microbiota
of healthy individuals, seems to be related to its immunomod-
ulatory and nourishing functions. In comparison with healthy
controls, IBD patients have decreased amounts of the
short-chain fatty acid (SCFA) producers. Butyrate, propionate
and acetate are SCFAs that are produced by bacteria as result
of resistant starch fermentation. These three SCFAs are
known to have anti-inﬂammatory properties [15,16]. The most
mentioned bacterium associated with IBD is the butyrate
producer Faecalibacterium prausnitzii (F. prausnitzii). Many
studies have found that IBD patients have a reduced amount
of this bacterium in their gut microbiota [17–20]. It has been
shown in patients with CD that F. prausnitzii also has a direct
anti-inﬂammatory effect by secreting metabolites that block
nuclear factor-jB activation and prevent the production of
interleukin-8 [20,21] (Fig. 1).
Butyrate produced by F. prausnitzii not only has direct
anti-inﬂammatory effects but also serves as a nutrient for the
colonocytes [13,22], and thereby prevents gut mucosa atrophy
[23] and colonocyte autophagy [24].
Indeed, a pilot non-randomized trial providing daily oral
butyrate for 8 weeks to IBD (CD) patients showed beneﬁcial
effects on (endoscopic and clinical) remission rates as well as
on markers of systemic inﬂammation [25].
The assumed relationship between the gut microbiota
composition and IBD is that the altered gut microbiota in IBD
patients has reduced anti-inﬂammatory properties and pro-
duces lower amounts of butyrate and other SCFAs. This may
lead to increased concentrations of proinﬂammatory media-
tors in the gut and impaired intestinal barrier function,
resulting in inﬂammation and increased gut permeability.
Altogether, these data indicate that the loss of certain bacterial
strains with speciﬁc immunomodulatory and mucosa-maintain-
ing functions results in gut dysbiosis, which may, besides
genetic factors of the host, contribute to the pathogenesis of
IBD. This dysbiosis in the gut could be restored by introducing
normal gut microbiota obtained from a healthy individual
without IBD.
FMT in humans, although in limited numbers, has also been
evaluated as a treatment for IBD. No randomized controlled
trials on this topic have been published yet, and outcomes of
case series show conﬂicting results. In addition, two systematic
reviews have addressed this subject [26,27]. The pooled data
of one systematic review [26] showed that, after FMT, the
majority of the patients had either reduction in the IBD
symptoms (19/25, 76.0%), were able to cease their medication
(13/17, 76.5%) within 6 weeks after FMT, or achieved
complete remission (15/24, 62.5%). Reported side effects
were not only abdominal tenderness, cramping, fever, and
diarrhoea, but also an activation of CD requiring medication.
Current evidence for the routine use of FMT against IBD is too
weak to justify its use in clinical practice, because of the lack of
data from properly designed randomized trials. However, at
present, there are several clinical trials underway (www.
clinicaltrials.gov), of which eight are randomized controlled
trials [28–35]. In two of these trials [32,35], candidates of
minor age are also eligible to participate, and one trial [34] is
focusing solely on the paediatric IBD population.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1119–1125
1120 Clinical Microbiology and Infection, Volume 20 Number 11, November 2014 CMI
IBS
IBS is a non-inﬂammatory gastrointestinal disorder character-
ized by abdominal pain and altered bowel movements in which
diarrhoea or constipation may dominate.
Many studies have evaluated the gut microbiota composition
of IBS patients. Patients with IBS have, in general, reduced
variability of the gut microbiota in comparison with the healthy
control group [36]. Moreover, one study [37] found that IBS
patients had lower amounts of lactobacilli and lactate-utilizing
bacteria, whereas the number of sulphate-reducing bacteria was
increased. Additionally, in vitro starch fermentation analysis
showed that the microbiota of IBS patients produced a lower
amount of butyrate, but greater amounts of sulphides and
hydrogen. It is likely that increased production of these gases
could promote IBS symptoms, as H2S has a major role in visceral
nociception [38]. In contrast to this, two other research groups
found increased amounts of lactobacilli among the gut micro-
biota of IBS patients [39,40]. These differences in the amounts of
lactobacilli might be the result of small numbers of participants in
the studies, differences in geographical location, and the large
symptom heterogeneity of IBS itself. However, a more consis-
tent ﬁnding is the reduced amount of biﬁdobacteria in both the
duodenalmicrobiota [41] and faecalmicrobiota [37,39,41] of IBS
patients in comparison with healthy controls.
In addition to the changed microbiota, IBS patients not only
have altered protein and carbohydrate energy metabolism
within the gut [39], but also increased amounts of acetic and
propionic acids, which are associated with both the severity of
abdominal pain and bloating symptoms [40]. These data
indicate that both the composition of the gut microbiota and
its metabolic functions are altered in IBS patients.
The authors of a recently published systematic review with
a meta-analysis [42] reported that probiotics are effective
treatments for IBS; however, which strain is the most
beneﬁcial remains unclear. As the faecal microbiota obtained
from a healthy individual represents the most natural compo-
sition of the human gut microbiota, FMT might be more
beneﬁcial than administering one speciﬁc bacterial strain.
Research in humans on the use of FMT against IBS has been
performed in case series only. One case series on FMT within
this patient group showed that 45 IBS patients with chronic
constipation underwent FMT. A total of 60% obtained
normalized defecation during a follow-up of 9–19 months
[43]. At present, one randomized clinical trial [44] is registered
(www.clinicaltrials.gov) that is evaluating FMT as a treatment
option for IBS.
F. prausnitzii
Colonocyte
Healthy gut microbiota
Gut microbiota of a healthy individual with
normal amount of F. prausnitzii and its anƟ-
inŇammatory metabolites. Suĸcient butyrate is
available to nourish the colonocytes and to
prevent an inŇammatory reacƟon.
IBD  gut microbiota
Reduced number of F. prausnitzii results in
shortage of butyrate and other anƟ-
inŇammatory metabolites. This provokes gut
inŇammaƟon (mediated by NF κ-B and IL-8). In
addiƟon, butyrate shortage causes mucosal
atrophy.
Butyrate and metabolites from F. prausnitzii prevent gut inŇammaƟon 
by blocking NF κ-B and IL-8 secreƟon.
Butyrate
IL-8
F. prausnitzii 
metabolite
Gut inŇammaƟon
NF-κB NF-κB NF-κB
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Luminal side
Luminal side
FIG. 1. Alterations within the gut microbiota under healthy conditions and in inﬂammatory bowel disease (IBD). IL-8, interleukin-8; NF-jB, nuclear
factor-jB.
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Obesity and Type 2 Diabetes
Obesity is a well-recognized public health problem in Western
society, but is also becoming a growing problem in developing
economies [45]. It is associated with many other morbidities,
such as type 2 diabetes and cardiovascular diseases. The
interaction between the gut microbiota and metabolism is
quite complex, and an important question here is whether the
microbiota composition associated with the obese phenotype
is the result or the cause of obesity.
Interesting animal studies have been performed to unravel
this causality. For example, germ-free mice do not become
obese and nor do they develop insulin resistance after
exposure to a high-fat diet [46–48]. Furthermore, the transfer
of gut microbiota from a conventionally raised mouse into a
germ-free mouse results in an increase in body fat content and
insulin resistance, despite reduced food intake [49].
Other animal studies have shown that the consumption of a
Western diet, containing high amounts of fat and sugars, leads
to a vast increase in members of the Firmicutes and a decrease
in members of the Bacteroidetes [50]. These results were in
concordance with the data from a mouse study, demonstrating
that a high-fat diet determines the composition of the gut
microbiota [51]. These animal studies show that obesity has
been associated with a decrease in members of the Bacteroi-
detes and an increase in members of the Firmicutes.
However, human studies have shown contradictory results
concerning the ratio between members of the Bacteroidetes and
Firmicutes between obese individuals in comparison with their
lean controls [52–54]. However, a meta-analysis showed that
decreases in members of both the Firmicutes and Biﬁdobacteria
are consistently associated with the human obese phenotype,
but an altered Bacteroidetes concentration is not [12]. Interest-
ingly, within the genus Lactobacillus, the increase in Lactobacillus
reuteri has been found to be linearly associated with an increase
in body mass index [55], whereas other species within the same
genus, such as Lactobacillus gasseri and Lactobacillus plantarum,
have been associated with a lean phenotype [56]. Nevertheless,
it has been hypothesized that the gut microbiota associated
with an obese phenotype of the host is able to harvest more
energy-rich molecules, especially SCFAs, derived from resistant
starch than the microbiota of lean individuals [54]. These
molecules provide the host with an additional amount of
energy, because some SCFAs can enter the citric acid cycle
after few modiﬁcations, or they can be used for gluconeogen-
esis, liponeogenesis, and proteogenesis [54,57–59].
One human study focusing solely on type 2 diabetes found
that affected individuals have a reduction in members of the
Firmicutes and an increase in members of the Bacteroidetes in
their gut microbiota in comparison with healthy controls.
Furthermore, the Bacteroidetes to Firmicutes ratio was posi-
tively correlated with reduced glucose tolerance [60].
The observation that obese individuals, whether or not they
have type 2 diabetes, have an altered gut microbiota in
comparison with control individuals resulted in the hypothesis
that FMT could be used as a treatment against metabolic
disorders. The most viable route for administering human gut
microbiota against metabolic disorders such as type 2 diabetes
would be the nasoduodenal route, because carbohydrate and
fatty acid uptake, which is crucial for the development of obesity
and insulin resistance, occurs primarily within the small intestine.
We were the ﬁrst group to perform a randomized study in
humans to evaluate the effect on insulin sensitivity of
nasoduodenal FMT with microbiota derived from lean donors
in patients with metabolic syndrome [61]. Patients who
received microbiota from lean donors had an increase in
peripheral insulin sensitivity 6 weeks after FMT in comparison
with peripheral insulin sensitivity prior to FMT. Also, an
increase in gut microbiota diversity was observed after FMT.
Additionally, the total bacterial abundance in small-intestine
biopsy samples showed no differences following FMT; how-
ever, there was an increase in the amount of the butyrate
producer Eubacterium hallii. This increase may have contributed
to the increased insulin sensitivity, as butyrate stimulates
energy metabolism and prevents insulin resistance [62].
Within this ﬁeld, another comparable randomized clinical
study from a different research group is registered at present
(www.clinicaltrials.gov) [63].
Interestingly, in another study [64], treatment with vanco-
mycin was demonstrated to result in impaired peripheral
insulin sensitivity in obese subjects with metabolic syndrome,
and decreased diversity of the gut microbiota. Members of the
phylum Firmicutes were the most affected; some Firmicutes taxa
increased and others decreased in abundance after FMT.
However, no changes in peripheral insulin sensitivity or in gut
microbiota composition were observed after exposure to
amoxycillin.
Multiresistant and Pathogenic
Microorganisms in theGastrointestinal Tract
The increase in antimicrobial resistance is a major public health
problem [65]. The greatest driving force behind antimicrobial
resistance is long-term exposure to antibiotics. Therefore, it is
not surprising that patients with the greatest risk for
acquisition of multiresistant microorganisms, such as
extended-spectrum b-lactamase (ESBL) producers and vanco-
mycin-resistant Enterococcus (VRE), are those with high levels
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of comorbidity, including malignancy, the use of immunosup-
pression, and intensive-care unit admission [66–68]. Systemic
antimicrobial therapy, which is mostly given to treat infection
outside the gastrointestinal tract, also has its impact on the gut
microbiota. It is hypothesized that a healthy heterogeneous gut
microbiota is able to prevent the colonization of the host
gastrointestinal tract by gut pathogens that may cause enteric
diseases. This phenomenon is described as colonization
resistance [69]. Exposure to antibiotics leads to the destruc-
tion of the healthy gut microbiota, and thereby selection of
resistant strains that remain behind and proliferate. Not much
research has been performed within this ﬁeld of antimicrobial
resistance and FMT in humans. However, a few interesting
animal studies have been published that have evaluated the
interaction between the gut microbiota and gut pathogenic
microorganisms. One study [70] has illustrated the association
between the genetic proﬁle and the gut microbiota between
two strains of mice that have different gut microbiota. In this
study, the transfer of Citrobacter rodentium (C. rodentium), which
is used as a rodent model for human enteropathogenic and
enterohaemorrhagic Escherichia coli (E. coli), was evaluated. In
NIH Swiss mice, C. rodentium infection is mild and self-limiting,
whereas in C3H/HeJ mice, C. rodentium infection was often
lethal [71]. Transplantation of the microbiota of NIH Swiss
mice to C3H/HeJ mice prior to C. rodentium infection resulted
in delayed pathogen colonization and delayed mortality of
C3H/HeJ mice [70].
Another research group demonstrated in mice that FMT
with microbiota containing Barnesiella species belonging the
phylum Bacteroidetes was able to decolonize the recipient from
VRE [72]. This study was conducted with mice bearing VRE in
their gastrointestinal tract that orally received gut microbiota
derived from VRE-negative mice. Within 7 days after FMT,
there was a reduction in faeces VRE density, and after 15 days
VRE was undetectable. The VRE clearance was enhanced in
mice who were recolonized by Barnesiella species after FMT.
Additionally, this group performed a study in humans, and
prospectively collected and compared faeces samples of
patients undergoing haemopoetic stem cell transplantation;
they found that patients who did not acquire VRE had higher
levels of Barnesiella species in their faeces samples than those
who did. These data support the postulate that, besides
microbiota diversity, the composition of the microbiota is also
important in maintaining colonization resistance.
In the future, it would be interesting to investigate whether
human FMT with faeces derived from a healthy individual could
be used against large-intestine colonization by VRE and other
multiresistant microorganisms.
Within our department, we are currently performing
studies on the feasibility of using FMT against gastrointestinal
colonization by resistant microorganisms such as ESBL
producers. As result of this, we recently published the ﬁrst
case report [73] of a patient in whom we decolonized the large
intestine from ESBL-producing E. coli with FMT. Despite this
being only a single case, it indicates that FMT might be effective
against multiresistant microorganisms residing in the large
intestine, and therefore opens a new research ﬁeld for the
implementation of FMT. However, to justify the standard use
of FMT against large-intestine colonization by multiresistant
microorganisms, further larger controlled studies are needed
to demonstrate the efﬁcacy of FMT.
Despite the limited available data, we are convinced that
FMT could be effective for decolonization of the large intestine
from enteropathogenic or multiresistant microorganisms,
because various species within the phyla Bacteroidetes, Firmi-
cutes and Actinobacteria confer direct and indirect colonization
resistance, not only against C. difﬁcile, but also against VRE,
E. coli, Salmonella species and Shigella species, by producing
antimicrobial substances and through modulation of the host
immune response [74]. Therefore, introducing a diverse gut
microbiota into a perturbed microbial environment could
restore gut microbiota diversity and subsequently result in
increased colonization resistance.
Conclusion
Advances in molecular techniques have given additional
insights in the many functions of the gut microbiota and its
interaction with the host, and have also revealed that many
diseases seem to have a certain association with the gut
microbiota to a greater or lesser extent (Table 1). Altering the
TABLE 1. Summary of the gut microbiota alterations asso-
ciated with inﬂammatory bowel disease, irritable bowel
syndrome, and metabolic disorders (obesity and type 2
diabetes)
Disorder Alterations within the gut microbiota
Inﬂammatory bowel disease Diversity ↓
Firmicutes and Bacteroidetes ↓
Faecalibacterium prausnitzii ↓
SCFAs ↓
Irritable bowel disease Diversity ↓
Biﬁdobacteria ↓
Altered amounts of lactobacilli
Altered carbohydrate and protein metabolism
within the gut
Production of acids and visceral nociceptive
gases ↑
Obesity Biﬁdobacteria ↓
Firmicutes ↓
Lactobacillus reuteri ↑
Harvesting of SCFAs by the host ↑
Type 2 diabetes Firmicutes ↓
Bacteroidetes ↑
SCFA, short-chain fatty acid.
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gut microbiota composition by FMT performed with the gut
microbiota derived from a healthy individual can be a novel
intervention for some diseases. At present, FMT has only been
shown to be effective against C. difﬁcile infection. Research is
still ongoing in the ﬁeld of IBD, IBS and type 2 diabetes in
humans. Even less is known about the possible therapeutic role
of FMT in the eradication of pathogenic and multiresistant
enteric microorganisms in the large intestine of humans.
Within this ﬁeld, further research has still to be performed.
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